New technique generates rod photoreceptors that integrate into the retina and brain.
Researchers funded by the National Eye Institute (NEI) have reversed congenital blindness in mice by changing supportive cells in the retina called Müller glia into rod photoreceptors. The findings advance efforts toward regenerative therapies for blinding diseases such as age-related macular degeneration and retinitis pigmentosa. A report of the findings appears online today in Nature. NEI is part of the National Institutes of Health.
“This is the first report of scientists reprogramming Müller glia to become functional rod photoreceptors in the mammalian retina,” said Thomas N. Greenwell, Ph.D., NEI program director for retinal neuroscience. “Rods allow us to see in low light, but they may also help preserve cone photoreceptors, which are important for color vision and high visual acuity. Cones tend to die in later-stage eye diseases. If rods can be regenerated from inside the eye, this might be a strategy for treating diseases of the eye that affect photoreceptors.”
Photoreceptors are light-sensitive cells in the retina in the back of the eye that signal the brain when activated. In mammals, including mice and humans, photoreceptors fail to regenerate on their own. Like most neurons, once mature they don’t divide.
Scientists have long studied the regenerative potential of Müller glia because in other species, such as zebrafish, they divide in response to injury and can turn into photoreceptors and other retinal neurons. The zebrafish can thus regain vision after severe retinal injury. In the lab, however, scientists can coax mammalian Müller glia to behave more like they do in the fish. But it requires injuring the tissue.
“From a practical standpoint, if you’re trying to regenerate the retina to restore a person’s vision, it is counterproductive to injure it first to activate the Müller glia,” said Bo Chen, Ph.D., associate professor of ophthalmology and director of the Ocular Stem Cell Program at the Icahn School of Medicine at Mount Sinai, New York.
“We wanted to see if we could program Müller glia to become rod photoreceptors in a living mouse without having to injure its retina,” said Chen, the study’s lead investigator.
In the first phase of a two-stage reprogramming process Chen’s team spurred Müller glia in normal mice to divide by injecting their eyes with a gene to turn on a protein called beta-catenin. Weeks later, they injected the mice’s eyes with factors that encouraged the newly divided cells to develop into rod photoreceptors.
The researchers used microscopy to visually track the newly formed cells. They found that the newly formed rod photoreceptors looked structurally no different from real photoreceptors. In addition, synaptic structures that allow the rods to communicate with other types of neurons within the retina had also formed. To determine whether the Müller glia-derived rod photoreceptors were functional, they tested the treatment in mice with congenital blindness, which meant that they were born without functional rod photoreceptors.
In the treated mice that were born blind, Müller glia-derived rods developed just as effectively as they had in normal mice. Functionally, they confirmed that the newly formed rods were communicating with other types of retinal neurons across synapses. Furthermore, light responses recorded from retinal ganglion cells — neurons that carry signals from photoreceptors to the brain — and measurements of brain activity confirmed that the newly-formed rods were in fact integrating in the visual pathway circuitry, from the retina to the primary visual cortex in the brain.
Chen’s lab is conducting behavioral studies to determine whether the mice have regained the ability to perform visual tasks such as a water maze task. Chen also plans to see if the technique works on cultured human retinal tissue.
The Latest on: Congenital blindness
via Google News
The Latest on: Congenital blindness
- Shoemaker Born Blind Putting Himself Through Aviation Schoolon January 12, 2021 at 1:29 am
Although many consider blindness an impediment to visual-oriented careers, Daniel Otieno Odongo, born blind, is set to beat the odds in realising his dream of becoming a pilot. Odongo, 29, was born on ...
- Aphantasia: The inability to visualize imageson January 8, 2021 at 10:43 am
A study investigating mind-blindness finds differences between people who lack the ability to create visual images in their mind and those who do not.
- 10 common infections that affect our sighton January 7, 2021 at 4:08 pm
These infections can cause a range of problems from simple irritation to blindness. Conjunctivitis is most commonly caused by viral infection, but it can also be a result of bacterial infection, ...
- ProQR Completes Enrollment of its Pivotal Trial of Sepofarsen for the Treatment of LCA10 Nasdaq:PRQRon January 6, 2021 at 11:37 pm
Sepofarsen is a potential first-in-class RNA therapy for the treatment of LCA10, a rare inherited retinal disorder that leads to blindness LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE ...
- Puzzle behind face blindness solved?on December 28, 2020 at 5:00 am
The causes of congenital face blindness -a condition in which a person s unable to use facial features to identify other people -can be traced back to an early stage in the perceptual process ...
- Extreme Heat Contributes to Rare Childhood Blindnesson December 21, 2020 at 4:00 pm
“The potential for maternal hyperthermia to cause congenital cataracts, a leading cause of avoidable blindness and visual impairment in children, should be more closely examined.” The Daily ...
- UF scientist recognized for work to cure blindnesson December 21, 2020 at 3:18 am
Hauswirth was among 13 scientists awarded The Sanford and Sue Greenberg Prize to End Blindness ... a genetic form of vision loss known as Leber congenital amaurosis type 2. His work with ...
- Hatteras-backed Durham gene firm raises $55 million to fight blindnesson December 16, 2020 at 10:10 am
A Triangle firm aiming to treat or prevent blindness has hauled in $55 million in a fundraising series led by a number of investors, including Durham's Hatteras Venture Partners. On Wednesday ...
- Eyeing phase 3, Atsena raises $55M financing for blindness gene therapyon December 16, 2020 at 4:30 am
The gene therapy is already in a phase 1/2 trial for Leber congenital amaurosis (LCA ... Venture Partners and the Foundation Fighting Blindness (FFB). It will also help bring forward two ...
via Bing News